

Fellows Forum Schedule of Events
April 29 - May 2, 2026
Fellows Forum
Fairmont Scottsdale Princess, Arizona

Wednesday, April 29, 2026		
Time	Description	Speaker
4:00 pm - 6:30 pm	Registration	
6:00 pm - 7:30 pm	Exhibitor Set-up	
7:30 pm - 9:00 pm	Welcome Reception/Dinner	
Thursday, April 30, 2026		
Time	Description	Speaker
7:00 AM - 8:00 AM	Breakfast & Registration	
8:00 am - 9:55 am	General Session 1 Moderators: Dr. Ramez Eskander, Dr. Christine Walsh, Dr. Brian Slomovitz	
8:00 am - 8:10 am	Welcome & Opening Remarks	
8:10 am - 9:00 am	Invited Guest Speaker: Judi Holler	Judi Holler
9:00 am - 9:10 am	DNA Damage Assessment Enhances Folate Receptor Alpha as a Predictive Biomarker in High-Grade Serous Ovarian Cancer	Carson Edwards, MD, University of Alabama Birmingham
9:10 am - 9:20 am	NSC59984 promotes pro-apoptotic p73 isoform ratios in TP53-mutated endometrial cancer cells	Natalie Posever, MD, Cleveland Clinic
9:20 am - 9:30 am	Integrating circulating tumor DNA and second-look laparoscopy for minimal residual disease detection and survival prediction in ovarian cancer	Helen Clark, MD, The University of Texas MD Anderson Cancer Center
9:30 am - 9:40 am	Dietary fiber promotes the antitumor response to anti-programmed cell death protein 1 (PD1) immunotherapy in a mouse model of cervical cancer	Reed O'Connor, MD, PhD, The Ohio State University
9:40 am - 9:55 am	Discussion/Audience Q&A	
9:55 am - 10:25 am	Coffee Break	
10:25 am - 12:15 pm	General Session 2 Moderators: Dr. Susan Modesitt, Dr. Floor Backes, Dr. Thomas Krivak	
10:25 am - 10:35 am	Referral frequency, uptake, and outcomes of germline genetic testing in patients with endometrial cancer	Alexandra Lamacki, MD, Roswell Park Cancer Center
10:35 am - 10:45 am	The impact of cervical stromal involvement on survival outcomes in stage IIIC endometrial carcinoma	Sarah Andres, DO, Memorial Sloan Kettering Cancer Center
10:45 am - 10:55 am	The effect of poly-ADP ribose polymerase inhibitor on progression free-survival in high-grade serous ovarian patients with an indeterminate homologous recombination deficiency status	Vasanti Jhaveri, MD, St. Luke's University Health Network

Fellows Forum Schedule of Events
April 29 - May 2, 2026
Fellows Forum
Fairmont Scottsdale Princess, Arizona

Thursday, April 30, 2026, Cont.		
Time	Description	Speaker
10:55 am - 11:05 am	Tirzepatide and intermittent energy restriction have anti-obesity and anti-tumorigenic effects in a pre-clinical mouse model of obesity-driven endometrial cancer	Alexandra Diggs, MD, University of North Carolina at Chapel Hill
11:05 am - 11:15 am	Discussion	
11:15 am - 11:25 am	Achieving conceiving? Factors associated with fertility outcomes following conservative management of endometrial intraepithelial neoplasia and endometrial cancer	Kelsey Roof, Emory University
11:25 am - 11:35 am	Glucagon-Like Peptide Receptor Agonists Are Associated with Superior 5-Year Overall Survival in Women with Endometrial Cancer	Justin Kim, MD, University of Iowa Health Care
11:35 am - 11:45 am	Tubo-ovarian cancer incidence among breast cancer patients with Hereditary Breast and Ovarian Cancer: An analysis of the Surveillance, Epidemiology and End Results Registry (SEER) - GeneLINK Dataset	Isabel Beshar, MD, MPhil MD Anderson Cancer Center
11:45 am - 11:55 am	Reducing Surgical Site Infections After Hysterectomy: A Quality Improvement Initiative to Standardize Vaginal Preparation	Kassandra Whitfield, MD, University of Kentucky
11:55 am - 12:05 pm	Impact of Hyperthermic Intraperitoneal Chemotherapy on Survival in Advanced Low-Grade Epithelial Ovarian and Primary Peritoneal Carcinoma: A Propensity-Matched National Cancer Database Study	Chrissy Liu, MD, University of South Florida
12:05 pm - 12:15 pm	Discussion	
12:15 pm - 12:30 pm	Day 1 Closing Remarks and Instruction for Team Building	
12:30 pm - 1:45 pm	Group Luncheon & Panel	
2:30 pm - 5:30 pm	Team Building Event	
7:00 pm - 9:00 pm	Dinner	

Fellows Forum Schedule of Events
April 29 - May 2, 2026
Fellows Forum
Fairmont Scottsdale Princess, Arizona

Friday, May 1, 2026		
Time	Description	Speaker
7:00 AM - 8:00 AM	Breakfast & Registration Help Desk	
8:00 am - 10:00 am	General Session 3 Moderators: Dr. Pamela Soliman, Dr. Kenneth Kim, Dr. Martin Martino	
8:00 am - 8:10 am	Welcome & Opening Remarks	
8:10 am - 8:20 am	Defining the role of omental sampling in clinical stage 1 high-grade endometrial carcinoma	Guido Rey Valzacchi, Memorial Sloan Kettering Cancer Center
8:20 am - 8:30 am	LEVER: Phase II trial of LEVOnorgestrel intrauterine device alone or in combination with the mTORC1 inhibitor EVERolimus for the treatment of atypical endometrial hyperplasia and early-stage endometrial cancer	Ravali Reddy, MD, The University of Texas MD Anderson Cancer Center
8:30 am - 8:40 am	Similar Survival Outcomes Following Adjuvant Chemotherapy Versus Observation in Low-Grade, Stage I Endometrioid Ovarian, Tubal and Peritoneal Carcinoma: A Propensity Score Weighted Analysis	Samantha Leite, MD, National Capital Consortium (Inova/Walter Reed/MedStar)
8:40 am - 8:50 am	CEMIP as a Potential Biomarker in Endometrial Cancer: Differential Expression in Metastatic Lesions and Implications for Diagnosis and Prognosis	Emily O'Brien, MD, University of Alabama at Birmingham
8:50 am - 9:05 am	Discussion	
9:05 am - 9:15 am	Temporally optimized sequential targeting of DNA damage response pathways in high grade serous ovarian cancer	Bianca Nguyen, MD, Moffitt Cancer Center
9:15 am - 9:25 am	Clinical features and incidence of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer	Anna Shvygin, MD, Memorial Sloan Kettering Cancer Center
9:25 am - 9:35 am	Generation of 3-D cellular endometrial and ovarian tumor spheroid models and use of HE4-high, chemo-naive human ascites to recreate tumor micro-environment in vitro	Megan Boyer, DO, MS, University of Rochester Medical Center
9:35 am - 9:45 am	Procedural volume trends in surgical training among gynecologic oncology fellows	Alysia Wiener, MD, Karmanos Cancer Institute, Detroit Medical Center
9:45 am - 10:00 am	Discussion	
10:00 am - 10:30 am	Faculty Lecture: Avoiding Imposer Syndrome in the OR: Setting Yourself up for Success	Dr. Heidi Gray
10:30 am - 11:00 am	Coffee Break	

Fellows Forum Schedule of Events
April 29 - May 2, 2026
Fellows Forum
Fairmont Scottsdale Princess, Arizona

Friday, May 1, 2026, Cont.		
Time	Description	Speaker
11:00 am - 1:00 pm	General Session 4 Moderators: Dr. Heidi Gray, Dr. Todd Tillmans, Dr. Christine Walsh	
11:00 am - 11:10 am	Efficacy and safety of fam-trastuzumab deruxtecan in recurrent HER2-positive endometrial cancer	Matthew Flint, MD, Memorial Sloan Kettering Cancer Center
11:10 am - 11:20 am	Exploratory analysis of patient-reported outcomes in individuals with newly diagnosed advanced ovarian cancer receiving neoadjuvant olaparib monotherapy vs. chemotherapy	Karen Haney, MD, MD Anderson Cancer Center
11:20 am - 11:30 am	Paired clinical molecular profiling of primary and recurrent tumors in patients with recurrent endometrial cancer	Diana Miao, MD, Brigham and Women's Hospital / Dana-Farber Cancer Institute
11:30 am - 11:40 am	Harnessing dietary n-3 fatty acids to enhance immunotherapy in ovarian cancer	Erin McMinn, MD, New York Presbyterian Hospital
11:40 am - 11:55 am	Discussion	
11:55 am - 12:05 pm	COVID-19 vaccination improves survival outcomes in patients with gynecologic malignancies treated with immune checkpoint inhibitors	Joseph Lafferty, MD, Cedars Sinai
12:05 pm - 12:15 pm	Feasibility and adherence to prehabilitation for patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer	Shilpa Mokshagundam, MD, Mayo Clinic
12:15 pm - 12:25 pm	Effectiveness and survival differences comparing sentinel lymph node biopsy and lymphadenectomy in patients undergoing radical hysterectomy for cervical cancer in the US	Alex Powers, MD, ScM, Massachusetts General Hospital
12:25 pm - 12:35 pm	The association between allostatic load at the time of ovarian cancer debulking surgery and patient outcomes	Ashley Duhon, MD, Roswell Park Comprehensive Cancer Center
12:35 pm - 12:45 pm	Can ChatGPT Take My Call? Evaluating AI in Gynecologic Oncology Telephone Triage	Ann Mercier, MD, Icahn School of Medicine at Mt Sinai Hospital
12:45 pm - 1:00 pm	Discussion	
1:00 pm - 2:00 pm	Group Luncheon: Invited Guest Speaker	Dr. Richard Barakat

Fellows Forum Schedule of Events
April 29 - May 2, 2026
Fellows Forum
Fairmont Scottsdale Princess, Arizona

Friday, May 1, 2026, Cont.		
Time	Description	Speaker
2:00 pm - 3:05 pm	General Session 5 Moderators: Dr. Mario Leitao, Dr. Pamela Soliman, Dr. Floor Backes	
2:00 pm - 2:10 pm	Preclinical assessment of combined PD-1 and CTLA-4 inhibition for adult type granulosa cell tumors of the ovary	Sarah McDonald, MD, Medical College of Wisconsin
2:10 pm - 2:20 pm	Assessment of GPT-5 as a clinician-reviewed adjunct to patient counseling in gynecologic oncology	Jenny Soiffer, MD, MPH, Montefiore Medical Center / Albert Einstein College of Medicine
2:20 pm - 2:30 pm	Disparities in Cervical Cancer Care Across Healthcare Settings: A Retrospective Cohort Analysis	Parisa Fallah, MD, MD Anderson Cancer Center
2:30 pm - 2:40 pm	Cromolyn sodium "MASTers" tumor growth in an immunocompetent high grade serous ovarian cancer in vivo model.	Areta Bojko, MD, Women & Infants Hospital Of Rhode Island
2:40 pm - 2:50 pm	Targeting steroid hormone receptor crosstalk for novel therapeutic strategies in endometrial cancer	Grace Lee, MD, University of Chicago
2:50 pm - 3:05 pm	Discussion & Day 2 Remarks	
Afternoon	Free Time	
7:00 pm - 9:00 pm	Group Dinner	

Fellows Forum Schedule of Events
April 29 - May 2, 2026
Fellows Forum
Fairmont Scottsdale Princess, Arizona

Saturday, May 2, 2026		
Time	Description	Speaker
7:45 am - 8:15 am	Breakfast & Registration/Help Desk	
8:15 am - 10:05 am	General Session 6 Moderators: Dr. Ramez Eskander, Dr. J. Michael Straughn, Dr. Susan Modesitt	
8:15 am - 8:25 am	Welcome & Opening Remarks	
8:25 am - 8:35 am	Combination of carboplatin and CHK1 inhibition to overcome platinum resistance in high grade serous ovarian cancer in preclinical mouse models.	Mackenzie Cummings, MD, Mitchell Cancer Institute, University of South Alabama
8:35 am - 8:45 am	Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts	Victoria Ettore, DO, MS, Yale University School of Medicine
8:45 am - 8:55 am	Utilization of guideline-concordant risk reducing gynecologic cancer surgery in the US	Danika Barry, MD, MPH, MPP, Brigham & Women's Hospital, Mass General Brigham
8:55 am - 9:10 am	Discussion	
9:10 am - 9:20 am	Combined PARP1 and CDK8 Inhibition Impairs Transcriptional Initiation and DNA Repair in High-Grade Serous Ovarian Cancer Models	William Vintzileos, MD, UT Southwestern Medical Center
9:20 am - 9:30 am	Somatic alterations in epigenetic regulator genes and their prognostic impact in endometrial cancer	Tiffany Jones, MD, MSc, University of Washington
9:30 am - 9:40 am	Development and validation of ex vivo patient derived organotypic tumor tissue culture models in gynecologic malignancies and dysplasia.	Eric Craig, MD, Icahn School of Medicine at Mount Sinai
9:40 am - 9:50 am	Mismatch repair protein profiling in endometrial intraepithelial neoplasia – an added opportunity for algorithmic management to optimize patient counseling	Cyrus Jalai, MD, Montefiore Medical Center
9:50 am - 10:05 am	Discussion	
10:05 am - 10:25 am	Coffee Break / Networking	
10:25 am - 10:45 am	Faculty Lecture: Time Management as a Way to Career and Personal Success	Dr. Christine Walsh
10:45 am - 11:00 am	Networking	
11:00 am - 12:15 pm	Awards Celebration Luncheon	